Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.
Jeff Patton, MD, chief executive officer of Tennessee Oncology, offers his reaction to CMS' proposal to ease restrictions on how Part D managed the 6 protected classes of drugs.
Transcript
How will CMS’ proposal to ease restrictions on how Part D manages the 6 protected classes of drugs impact community oncologists and their patients?
Step edits in general are becoming very onerous. We have to hire staff, we have to have extra inventory, and we follow clinical guidelines, so we’re doing evidence-based medicine. So, they have to jump through these extra hoops and have other people tell us how care should be delivered is really onerous. We are not a fan of step edits in general, and not having excluded classes in Part D that were previously were, we’re not fans.
IgE Mediation in Pediatric Atopic Dermatitis, Concurrent Immune Disorders: Amy Paller, MD
August 4th 2025Amy Paller, MD, pediatric dermatologist and clinical researcher at Northwestern Medicine's Feinberg School of Medicine, discussed the potential impact of reducing immunoglobulin E (IgE) levels in pediatric patients with atopic dermatitis.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
GLP-1 Receptor Agonists Reduce Adverse Cardiovascular Outcomes, Improve Survival
August 2nd 2025Studies found that glucagon-like peptide-1 (GLP-1) receptor agonists were valuable tools in improving outcomes and survival in those with coronary plaque and after ST-elevation myocardial infarction.
Read More